ON DEMAND WEBINAR
Duration: 1 hour

Neurogenetic disorders that impact how the brain functions affect up to three percent of children, but available evaluation tools aren’t sensitive enough to detect change in their developmental skills. This poses a challenge for clinical trial sponsors who are trying to assess potential treatments. In addition, detailed natural history studies haven’t done enough to characterize the effects of age and the stage of disease of neurogenetic disorders. 

Recent research calls for new and improved tools to test treatments of all pediatric neurogenetic diseases—something researchers and trial sponsors are eager to see. In this webinar, join experts to better understand the challenges to treatment in these trial settings. You’ll learn:

• Why available evaluation tools may not always be effective in clinical trials
• The advantages of precise tools and metrics in developing clinical trial protocols
• Why growth scale values are a better metric for measuring developmental change during trials

SPEAKERS

Elsa G. Shapiro, Ph.D., A.B.P.P.
Professor of Pediatrics and Neurology, Division of Pediatric Behavioral Neuroscience
University of Minnesota, Minneapolis, MN

Julie Eisengart PhD, LP,
Pediatric Neuropsychologist
University of Minnesota

Paul Harmatz MD
Pediatric Gastroenterologist
UCSF Benioff Children’s Hospitals